Our technologies enable us to rapidly develop novel immunotherapies against targets of interest with potential partners.
Our Lead Programs
Kleo is rapidly advancing multiple candidates against a range of hematological and solid tumors
NEW HAVEN, Conn., June 18, 2019 /PRNewswire/ — Kleo Pharmaceuticals, Inc. (Kleo), an immuno-oncology company developing next-generation synthetic bispecific compounds designed to emulate or enhance […] Read Post
NEW HAVEN, Conn., Feb. 26, 2019 /PRNewswire/ — Kleo Pharmaceuticals Inc., a unique immuno-oncology company developing next-generation bispecific compounds designed to emulate or […] Read Post
Doug Manion, CEO of Kleo, talks about the company’s platform technology, why he thinks it will produce safer and more […] Read Post